Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook

gemcitabine

  • Open Access
    Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
    Yuxiao Liu, Xiaofan Guo, Peijun Xu, Yuning Song, Jing Huang, Xingyun Chen, Wenbo Zhu, Jihui Hao and Song Gao
    Cancer Biology & Medicine September 2024, 21 (9) 799-812; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0036
  • You have access
    Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
    Zhou Zhu, Hui Tang, Jinrong Ying, Yuejuan Cheng, Xiang Wang, Yingyi Wang and Chunmei Bai
    Cancer Biology & Medicine October 2023, 20 (10) 765-778; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0189
  • You have access
    VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo
    Guangbo Kang, Min Hu, He Ren, Jiewen Wang, Xin Cheng, Ruowei Li, Bo Yuan, Yasmine Balan, Zixuan Bai and He Huang
    Cancer Biology & Medicine August 2021, 18 (3) 772-787; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0568
  • You have access
    Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy
    Ye Tian, Changyu Sun, Limeng Zhang and Yuan Pan
    Cancer Biology & Medicine May 2018, 15 (2) 157-164; DOI: https://doi.org/10.20892/j.issn.2095-3941.2017.0182
  • You have access
    Gemcitabine and Docetaxel as a Second-Line Treatment in Advanced Soft Tissue Sarcomas
    Hend Ahmed El-Hadaad and Hanan AHMED WAHBA
    Clinical Oncology and Cancer Research September 2011, 8 (3) 133-137; DOI: https://doi.org/10.1007/s11805-011-0571-y
  • You have access
    Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer
    Xia Liu, Li Ma, Jinhui Tian and Kehu Yang
    Clinical Oncology and Cancer Research December 2009, 6 (6) 412-417; DOI: https://doi.org/10.1007/s11805-009-0412-4
  • You have access
    Comparative Study of Gemcitabine Plus Cisplatin and Gemcitabine Plus Fluorouracil in the Treatment of Advanced Pancreatic Cancer
    Yongqian Shu, Lianke Liu, Lingxiang Liu, Puwen Huang, Kaihua Lu and Yongmei Yin
    Chinese Journal of Clinical Oncology February 2004, 1 (1) 63-67;

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire